Endoscopic Submucosal Dissection Market: as Japan and South Korea national health insurance reimbursement for gastric, oesophageal, and colorectal ESD generates the world's highest per-capita ESD procedure volumes and provides the clinical evidence base that is driving ESGE 2024 guideline endorsement in Europe and ASGE acceptance in North America, so Olympus's 20-year ESD knife leadership through DualKnife J, TriangleTipKnife J, and HookKnife J with integrated water jet creates deep instrument familiarity among trained endoscopists that sustains its installed base dominance, and so the Erbe HybridKnife I-Type May 2024 launch and Olympus Retentia HemoClip March 2025 introduction are improving procedure efficiency and post-resection closure to expand ESD adoption at lower-volume Western training programmes.

The global endoscopic submucosal dissection market size was USD 496.4 Million in 2025 and is expected to register a revenue CAGR of 8.1% during the forecast period. Market revenue growth is driven by factors such as Japan and South Korea's mandatory national health insurance reimbursement for gastric, oesophageal, and colorectal ESD that generates the world's highest per-capita ESD procedure volumes and the clinical evidence base driving Western adoption, the ESGE April 2024 emphasis on rising ESD acceptance for early gastric and colorectal cancer treatment that is expanding the European procedure base beyond established expert centres, as well as new product launches including the Erbe HybridKnife I-Type in May 2024 and the Olympus Retentia HemoClip in March 2025 that reduce procedure time and post-resection complication rates. The first driving factor is the East Asian reimbursement and clinical evidence model. Japan's National Health Insurance has covered ESD for early gastric cancer since 2006, oesophageal cancer since 2008, and colorectal neoplasia since 2012, establishing government-mandated reimbursement that ensures ESD accessibility at all eligible patients at accredited Japanese endoscopy centres and generating the high annual procedure volumes that have produced the large published clinical evidence base demonstrating ESD's en bloc resection superiority over endoscopic mucosal resection for lesions exceeding 20 millimetres. GLOBOCAN 2022, published by Bray et al. in CA: A Cancer Journal for Clinicians in 2024, documented approximately 970,000 new stomach cancer cases globally in 2022, making gastric cancer the fifth most common cancer by incidence, with the highest incidence concentrated in Eastern Asia where Japan's approximately 40,000 and China's approximately 360,000 annual gastric cancer cases generate the largest ESD-amenable patient volumes globally. The second driving factor is Olympus Corporation's FY2025 Therapeutic Solutions Business revenue of JPY 361,188 Million encompassing GI EndoTherapy instruments including ESD knives marketed globally, anchoring the ESD knife commercial base. The third driving factor is the Olympus-Proximie partnership in October 2024 enabling real-time OR video collaboration and remote ESD proctoring, expanding training reach to gastroenterology programmes without on-site ESD-trained mentors. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way each new Western endoscopy programme that trains to ESD competency generates a sustained multi-year per-procedure ESD knife and accessory consumption annuity, because ESD knife use is single-use per-procedure at most institutions consuming one to three knives per ESD case depending on lesion complexity at per-unit pricing of approximately USD 80 to USD 200 for conventional ESD knives and USD 150 to USD 350 for integrated water jet hybrid knives, compounding the revenue base as the number of trained ESD endoscopists grows. Once an endoscopy programme has invested in ESD fellowship training, procured the Olympus DualKnife J or HookKnife J as its primary ESD knife, and established the electrosurgical generator and submucosal injection agent protocols, each ESD case that the programme performs generates per-case device revenue from the knife, closure clips, haemostasis accessories, and injection agents at a total per-procedure spend of USD 400 to USD 1,200 that exceeds the per-procedure device spend of standard endoscopic mucosal resection. As a result, the ESD market revenue compounds as the number of trained endoscopists in North America and Europe grows, and the forecast tilts toward programmes adopting ESD for the colorectal indication where large adenoma ESD is growing faster than the gastric indication in Western markets. For instance, Olympus reported total R&D expenditure of USD 687.1 Million in FY2024 per the company's financial disclosures, reflecting continued investment in ESD instrument innovation, and in January 2025, Olympus Latin America acquired the distribution business from Sur Medical SpA in Chile to establish direct ESD instrument distribution, one of several Olympus commercial infrastructure investments that expand the global ESD distribution network. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the mandatory national health insurance reimbursement framework in Japan and South Korea that ensures ESD is accessible to all eligible patients at accredited endoscopy centres, generating high annual procedure volumes that have produced the large published clinical evidence base demonstrating ESD superiority over endoscopic mucosal resection. Japan's NHI coverage of ESD for early gastric cancer since 2006, oesophageal cancer since 2008, and colorectal neoplasia since 2012 means each newly screen-detected early GI cancer eligible for curative resection automatically enters the ESD treatment pathway at accredited Japanese endoscopy centres, with Japan's national upper GI endoscopy screening programme for gastric cancer detection generating screen-detected early gastric cancer lesions at the world's highest volume. GLOBOCAN 2022 estimated approximately 970,000 new stomach cancer cases globally in 2022, with China alone accounting for approximately 360,000 and Japan approximately 40,000 of those cases, collectively representing the largest ESD-amenable early gastric cancer patient volumes globally. The WHO Global Status Report on Cancer documented approximately 660,000 gastric cancer deaths in 2022, making it the fourth leading cause of cancer death globally, establishing the oncological urgency that sustains government reimbursement policy for early detection and curative endoscopic resection. Olympus Corporation's collaboration with Japan's National Cancer Center Hospital from the 1990s, producing the first ESD knife in 2002, and the company's FY2025 Therapeutic Solutions Business revenue of JPY 361,188 Million encompassing GI EndoTherapy ESD knives confirm that the East Asian ESD procedure volume drives the majority of global ESD instrument revenue. The ESGE's April 2024 emphasis on rising ESD acceptance for early gastric and colorectal cancer at UEG Week 2024 confirmed the directional trajectory from East Asian origin to global standard of care at academic gastroenterology programmes. These are some of the key factors driving revenue growth of the market.

The second driver is the acceleration of ESD-specific product innovation in 2024 and 2025 that reduces procedure complexity and complication rates at the training programme level, directly targeting the time and risk barriers that have limited ESD diffusion to major academic centres in North America and Europe. Erbe Elektromedizin GmbH launched the HybridKnife I-Type in May 2024, offering multifunctional capabilities that combine endoscopic cutting, submucosal injection via integrated high-pressure water jet, and tissue coagulation in a single ESD instrument, eliminating the device exchange step between submucosal injection needle and electrosurgical cutting knife that adds procedure time and operator complexity to conventional two-instrument ESD workflows. For training programmes where procedure time allocation is a constraint on case volume because health systems are reluctant to reserve long endoscopy suite slots for a still-developing technique, the HybridKnife I-Type's time saving directly translates into more ESD cases per endoscopy list and faster trainee skill accumulation. In March 2025, Olympus introduced the Retentia HemoClip with 360-degree full rotation capability for reliable wound closure after ESD resection, enabling clip placement at any wound angle regardless of endoscope approach axis with single-click deployment that accelerates the post-resection closure step and reduces the risk of delayed bleeding from large ESD mucosal defects. Post-ESD delayed bleeding occurs in approximately 5 to 7% of cases per published clinical series, and a premium closure device that can reliably secure large mucosal defects at challenging wound angles reduces the clinical anxiety that limits ESD programme expansion at centres without experienced haemostasis capability. FUJIFILM Healthcare Europe introduced the EndoGel ESD training simulator in April 2024 at UEG Week, providing a lifelike tissue model for practising submucosal injection technique and knife manoeuvring without patient risk. The effect on the market is a combined reduction in the time, complexity, and complication barriers that have maintained ESD as an exclusively specialist procedure, expanding the addressable training programme base in North America and Europe. These are some of the key factors driving revenue growth of the market.

Olympus Corporation disclosed in its FY2025 consolidated results that Endoscopic Solutions Business revenue reached JPY 636,144 Million at 8.4% year-on-year growth, with Therapeutic Solutions Business revenue of JPY 361,188 Million encompassing GI EndoTherapy ESD instruments marketed globally. The ESGE's April 2024 UEG Week 2024 confirmation of rising ESD acceptance for early gastric and colorectal cancer at European centres establishes the guideline endorsement framework that academic European gastroenterology programmes require before expanding ESD programme establishment beyond the small number of established European expert ESD centres.

The third driver is the commercial infrastructure and training access expansion that is extending ESD procedure volume growth into geographic markets and training programme tiers that previously lacked the direct Olympus clinical sales support and expert proctoring access required to establish new ESD programmes. In October 2024, Olympus partnered with Proximie, a digital operating room collaboration platform, to enable real-time OR video collaboration and remote proctoring for ESD training, allowing expert ESD endoscopists to provide live procedural feedback to trainee endoscopists at remote institutions via high-definition OR video streaming, significantly expanding ESD training reach to gastroenterology programmes in North America, Europe, and Asia Pacific without on-site ESD-trained mentors. In January 2025, Olympus Latin America acquired the distribution business from Sur Medical SpA in Chile, establishing direct sales and service operations for Olympus medical technology in Chile including the full therapeutic endoscopy portfolio encompassing ESD knives, EVIS X1 endoscopy systems, and ESD accessories, enabling Olympus to build direct customer relationships with Chilean hospital endoscopy programmes and expand ESD programme development in the Latin American market. The ACS Cancer Facts and Figures 2024 estimated approximately 26,890 new stomach cancer cases in the United States in 2024, with the number of US academic centres with trained ESD endoscopists growing from approximately 15 in 2015 to an estimated 120 to 150 by 2025, demonstrating the compound effect of training infrastructure expansion on procedure volume growth over a decade. The effect on the market is progressive revenue growth as each new ESD training programme established generates a multi-year per-procedure ESD device consumption annuity. These are some of the key factors driving revenue growth of the market.

However, the endoscopic submucosal dissection market faces adoption constraints from the steep learning curve that limits ESD practice to a small number of centres in most Western countries, the risk of procedure-related complications, and the availability of endoscopic mucosal resection as a simpler alternative for smaller lesions. Because ASGE ESD Task Force data confirm competency requires 30 to 50 supervised procedures before independent practice and most Western hospitals perform fewer than 10 ESD procedures per endoscopist annually, a structural training bottleneck limits ESD diffusion beyond major academic medical centres with established international fellowship programmes and prevents ESD from becoming a routine community gastroenterology procedure. Colorectal ESD's perforation risk of approximately 3 to 6% per published clinical series substantially exceeds gastric ESD at 2 to 4%, due to the thinner colonic wall and complex luminal anatomy, constraining colorectal ESD adoption at programmes without immediate surgical backup capability for perforation management and limiting the fastest-growing Western ESD indication to academic centres with dedicated colorectal ESD training tracks. Endoscopic mucosal resection remains available as a simpler alternative for tumours below 20 millimetres, limiting ESD's addressable indication base in Western markets to large lesions requiring en bloc resection for curative margins and reducing the total ESD-eligible case volume at programmes where smaller lesions continue to be managed by piecemeal EMR without ESD skill requirements. These factors substantially limit endoscopic submucosal dissection market growth over the forecast period.

Based on product, the global ESD market is segmented into ESD knives, gastroscopes and endoscopes, haemostasis and closure devices, injection agents, and traction devices and accessories. ESD knives hold the largest revenue share at approximately 41% of 2025 market revenue, because ESD knives are single-use per-procedure instruments at most institutions consuming one to three knives per case depending on lesion complexity, with standard per-unit pricing of approximately USD 80 to USD 200 for conventional ESD knives and USD 150 to USD 350 for integrated water jet hybrid knives generating sustained high-volume per-procedure consumable revenue. Olympus's DualKnife J, TriangleTipKnife J, and HookKnife J with integrated water jet function represent the current standard ESD knife portfolio, with deep institutional familiarity among trained endoscopists who learned ESD technique with Olympus instruments. Erbe's HybridKnife I-Type launched in May 2024 and HybridKnife T-Type compete in the hybrid knife segment. Haemostasis and closure devices, encompassing ESD-specific haemostatic clips including the Olympus Retentia HemoClip launched in March 2025, coagulation forceps, and closure clip systems, are expected to register a rapid revenue growth rate in the global ESD market over the forecast period, driven by the clinical requirement for reliable post-ESD wound closure at large resection defects where delayed bleeding occurs in 5 to 7% of cases and each ESD case typically consumes two to six closure clips at USD 60 to USD 120 per clip.

Early gastric cancer indication is expected to account for the largest revenue share in the global endoscopic submucosal dissection market during the forecast period

Based on indication, the global ESD market is segmented into early gastric cancer, early colorectal neoplasia, and early oesophageal cancer and Barrett's oesophagus. Early gastric cancer holds the largest revenue share at approximately 56% of 2025 market revenue, anchored by Japan and South Korea's mandatory NHI reimbursement, the world's highest gastric cancer incidence in Eastern Asia with China's approximately 360,000, Japan's approximately 40,000, and South Korea's approximately 28,000 new gastric cancer cases annually per GLOBOCAN 2022 regional estimates, and Olympus's long-established dominant commercial position at Asian gastric cancer ESD programmes. Early colorectal neoplasia is expected to register the fastest revenue growth rate in the global ESD market over the forecast period, driven by the growing ASGE endorsement of ESD for large colorectal lesions exceeding 20 millimetres, ESGE 2024 confirmation of colorectal ESD acceptance for European programmes, and the expansion of colorectal ESD training at US advanced endoscopy fellowship programmes where colorectal ESD has become the primary growth indication for Western ESD programme establishment.

Asia Pacific region accounted for the largest revenue share in the global ESD market in 2025

Based on geography, Asia Pacific held the dominant ESD market revenue share at approximately 52% of 2025 global revenue. Japan and South Korea drive the regional position through mandatory NHI reimbursement and the world's highest ESD procedure volumes per capita, with the gastric cancer incidence in China, Japan, and South Korea collectively representing approximately 430,000 of the 970,000 annual global gastric cancer cases per GLOBOCAN 2022. South Korea's population-based cancer screening programme for gastric cancer achieves early-stage detection rates of approximately 50 to 60% in screen-detected cases, generating a proportionally high curative ESD-eligible case volume at Korean university hospitals. North America and Europe are expected to register the fastest revenue growth rates within the ESD market over the forecast period, with US academic ESD centres growing from approximately 15 in 2015 to an estimated 120 to 150 by 2025 and ESGE 2024 endorsement driving European programme establishment.

Based on regional analysis, the endoscopic submucosal dissection market in Asia Pacific accounted for the largest revenue share in 2025 at approximately 52% of global revenue. Japan and South Korea drive the regional position through mandatory NHI reimbursement for ESD across gastric, oesophageal, and colorectal indications, the world's highest ESD-trained endoscopist density per capita, and the 20-year clinical evidence base establishing ESD as standard of care for early GI cancer resection. Olympus Corporation's Therapeutic Solutions Business revenue of JPY 361,188 Million in FY2025, primarily generated across Asian markets through the company's direct sales organisations in Japan, South Korea, China, and broader Asia Pacific, anchors the ESD instrument revenue base. GLOBOCAN 2022 estimated approximately 360,000 new gastric cancer cases in China, approximately 40,000 in Japan, and approximately 28,000 in South Korea, collectively representing the largest ESD-amenable early gastric cancer concentration globally.

The market in North America is expected to register the fastest revenue growth rate in the global ESD market over the forecast period. The United States represents the primary North American ESD market, with ESD adoption accelerating from near-zero in 2013 when the first ASGE-JGES joint ESD course was introduced to an estimated 5,000 to 8,000 annual US ESD procedures by 2025 at academic medical centres with dedicated advanced endoscopy fellowship programmes. The ACS Cancer Facts and Figures 2024 estimated approximately 26,890 new US stomach cancer cases in 2024, and growing US colorectal ESD adoption is driven by ASGE's increasing endorsement of ESD for large colorectal lesions exceeding 20 millimetres where piecemeal EMR carries higher recurrence risk.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, Italy, and Spain represent the five largest national ESD markets within Europe. ESGE's April 2024 clinical endorsement of rising ESD acceptance for early gastric and colorectal cancer at UEG Week 2024, confirming ESD as the preferred technique for lesions exceeding 20 millimetres, is driving ESD programme establishment at European university hospitals beyond the small number of established expert centres. FUJIFILM Healthcare Europe's April 2024 EndoGel training simulator and Olympus-Proximie remote proctoring partnership address the training access bottleneck that has been the primary European adoption constraint.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil, Mexico, Chile, and Colombia represent the four largest national ESD markets. Brazil's major academic medical centres in Sao Paulo and Rio de Janeiro have established ESD training programmes in partnership with Japanese and Korean endoscopy societies, and the gastric cancer burden in Latin America, influenced by Helicobacter pylori infection prevalence, supports ESD as a curative treatment modality for early-stage cases detected at academic programmes. In January 2025, Olympus Latin America acquired Sur Medical Chile's distribution business to establish direct ESD instrument sales in the Chilean market, strengthening the commercial infrastructure that supports ESD programme development. Iran-US sanctions and global trade disruptions have maintained elevated specialty steel and polymer material costs affecting ESD knife manufacturing distribution pricing in Latin America through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia, the UAE, Turkey, Egypt, and South Africa represent the primary national ESD markets. Mediclinic Parkview Hospital in Dubai introduced ESD in February 2023 as a minimally invasive procedure for treating oesophageal, gastric, and colorectal cancers including Barrett's oesophagus, representing one of the first commercial ESD programme launches in the GCC. Saudi Arabia's King Abdulaziz Medical City and the King Faisal Specialist Hospital and Research Centre represent the primary ESD-capable endoscopy centres in the Saudi market, with Healthy Middle East 2025 health initiatives creating new tertiary hospital endoscopy programme procurements.